Future Oncology

Papers
(The H4-Index of Future Oncology is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-03-01 to 2025-03-01.)
ArticleCitations
Spectrum of Lymphoma Subtypes Based on the Latest World Health Organization Classification in Southern Iran from 2000 to 2011101
Bidirectional Deep Neural Networks to Integrate RNA and DNA Data for Predicting Outcome for Patients with Hepatocellular Carcinoma78
Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma72
Treatment of the blood cancer polycythemia vera with ruxolitinib in the MAJIC-PV study: a plain language summary65
Plain language summary: tarlatamab for patients with previously treated small cell lung cancer58
Genetic variants in mitochondrial sirtuins associated with brain tumor risk: a case–control study57
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)52
Association of Facility Type With Overall Survival in Patients with Nonsurgically Managed Pancreatic Cancer47
A Plain Language Summary of the ASCENT Study: Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer43
Nomogram Predicting Prostate Cancer in Patients with Negative Prebiopsy Multiparametric Magnetic Resonance41
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: a plain language summary of the DESTINY-Breast04 study39
Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TAL39
CASE (CemiplimAb-rwlc Survivorship and Epidemiology): a study in advanced basal cell carcinoma38
Levetiracetam and valproic acid in glioma: antiseizure and potential antineoplastic effects37
An observational study of hospitalized COVID-19 patients with cancer in San Diego county36
Decoding clinical trial jargon: helping people understand theefficacy end points used in cancer trials36
Cutaneous Adverse Events Associated with PD-1 Inhibitor-based Therapy in Patients with Non-Small-Cell Lung Cancer36
6 th Symposium on Primary Breast Cancer in Older Women35
Should One Use the Combination of Abiraterone and Poly(ADP-ribose) Polymerase Inhibitors as First-Line Therapy for all Patients with Metastatic Castration-Resistant Prostate Cancer?35
Prognostic Factors Affecting Infantile Medulloblastoma Outcomes in the Molecular Era: A 12-year Single-Center Experience from Egypt34
Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma32
Resveratrol and miR-200c: insights into the prevention of oral squamous cell carcinoma31
miRNA-767 and its binding site polymorphism in the mTOR gene act as potential biomarkers for female reproductive cancers30
Capecitabine Maintenance Therapy in Metastatic Colorectal Cancer Patients with no Evidence of Disease: CAMCO Trial30
Results of a survey study on health professionals’ perceptions of tumor boards in Brazil29
Sex bias phenomenon in oral cancer: an insight28
Radiofrequency ablation versus stereotactic body radiation therapy for hepatocellular carcinoma: a meta-regression28
Prognostication for Surgically Treated Papillary Renal Cell Carcinoma: Which Model is the Optimal Choice?28
Prediction model based on radiomics and clinical features for preoperative lymphovascular invasion in gastric cancer patients28
The Power of Hope: Views of Ovarian Cancer Patients on How Maintenance Therapy Affects Their Lives (VOCAL)28
Brain Injury after Cranial Radiotherapy Combined with Immunotherapy for Brain Metastases in Lung Cancer: A Retrospective Study28
0.10607981681824